273 related articles for article (PubMed ID: 21335545)
1. Protein kinase C δ is a downstream effector of oncogenic K-ras in lung tumors.
Symonds JM; Ohm AM; Carter CJ; Heasley LE; Boyle TA; Franklin WA; Reyland ME
Cancer Res; 2011 Mar; 71(6):2087-97. PubMed ID: 21335545
[TBL] [Abstract][Full Text] [Related]
2. PKCδ regulates integrin αVβ3 expression and transformed growth of K-ras dependent lung cancer cells.
Symonds JM; Ohm AM; Tan AC; Reyland ME
Oncotarget; 2016 Apr; 7(14):17905-19. PubMed ID: 26918447
[TBL] [Abstract][Full Text] [Related]
3. Co-dependency of PKCδ and K-Ras: inverse association with cytotoxic drug sensitivity in KRAS mutant lung cancer.
Ohm AM; Tan AC; Heasley LE; Reyland ME
Oncogene; 2017 Jul; 36(30):4370-4378. PubMed ID: 28368426
[TBL] [Abstract][Full Text] [Related]
4. Oncogenic KRAS-induced epiregulin overexpression contributes to aggressive phenotype and is a promising therapeutic target in non-small-cell lung cancer.
Sunaga N; Kaira K; Imai H; Shimizu K; Nakano T; Shames DS; Girard L; Soh J; Sato M; Iwasaki Y; Ishizuka T; Gazdar AF; Minna JD; Mori M
Oncogene; 2013 Aug; 32(34):4034-42. PubMed ID: 22964644
[TBL] [Abstract][Full Text] [Related]
5. Oncogenic KRAS-induced interleukin-8 overexpression promotes cell growth and migration and contributes to aggressive phenotypes of non-small cell lung cancer.
Sunaga N; Imai H; Shimizu K; Shames DS; Kakegawa S; Girard L; Sato M; Kaira K; Ishizuka T; Gazdar AF; Minna JD; Mori M
Int J Cancer; 2012 Apr; 130(8):1733-44. PubMed ID: 21544811
[TBL] [Abstract][Full Text] [Related]
6. Protein kinase Cδ inactivation inhibits cellular proliferation and decreases survival in human neuroendocrine tumors.
Chen Z; Forman LW; Miller KA; English B; Takashima A; Bohacek RA; Williams RM; Faller DV
Endocr Relat Cancer; 2011 Dec; 18(6):759-71. PubMed ID: 21990324
[TBL] [Abstract][Full Text] [Related]
7. Blockage of PAK1 alleviates the proliferation and invasion of NSCLC cells via inhibiting ERK and AKT signaling activity.
Song P; Song B; Liu J; Wang X; Nan X; Wang J
Clin Transl Oncol; 2021 Apr; 23(4):892-901. PubMed ID: 32974862
[TBL] [Abstract][Full Text] [Related]
8. Protein kinase C delta is required for survival of cells expressing activated p21RAS.
Xia S; Forman LW; Faller DV
J Biol Chem; 2007 May; 282(18):13199-210. PubMed ID: 17350960
[TBL] [Abstract][Full Text] [Related]
9. CHUK/IKK-α loss in lung epithelial cells enhances NSCLC growth associated with HIF up-regulation.
Chavdoula E; Habiel DM; Roupakia E; Markopoulos GS; Vasilaki E; Kokkalis A; Polyzos AP; Boleti H; Thanos D; Klinakis A; Kolettas E; Marcu KB
Life Sci Alliance; 2019 Dec; 2(6):. PubMed ID: 31792060
[TBL] [Abstract][Full Text] [Related]
10. Interactions between wild-type and mutant Ras genes in lung and skin carcinogenesis.
To MD; Rosario RD; Westcott PM; Banta KL; Balmain A
Oncogene; 2013 Aug; 32(34):4028-33. PubMed ID: 22945650
[TBL] [Abstract][Full Text] [Related]
11. Contributions of KRAS and RAL in non-small-cell lung cancer growth and progression.
Guin S; Ru Y; Wynes MW; Mishra R; Lu X; Owens C; Barn AE; Vasu VT; Hirsch FR; Kern JA; Theodorescu D
J Thorac Oncol; 2013 Dec; 8(12):1492-501. PubMed ID: 24389431
[TBL] [Abstract][Full Text] [Related]
12. Selective requirement for Mediator MED23 in Ras-active lung cancer.
Yang X; Zhao M; Xia M; Liu Y; Yan J; Ji H; Wang G
Proc Natl Acad Sci U S A; 2012 Oct; 109(41):E2813-22. PubMed ID: 22988093
[TBL] [Abstract][Full Text] [Related]
13. Knockdown of oncogenic KRAS in non-small cell lung cancers suppresses tumor growth and sensitizes tumor cells to targeted therapy.
Sunaga N; Shames DS; Girard L; Peyton M; Larsen JE; Imai H; Soh J; Sato M; Yanagitani N; Kaira K; Xie Y; Gazdar AF; Mori M; Minna JD
Mol Cancer Ther; 2011 Feb; 10(2):336-46. PubMed ID: 21306997
[TBL] [Abstract][Full Text] [Related]
14. ILT4 inhibition prevents TAM- and dysfunctional T cell-mediated immunosuppression and enhances the efficacy of anti-PD-L1 therapy in NSCLC with EGFR activation.
Chen X; Gao A; Zhang F; Yang Z; Wang S; Fang Y; Li J; Wang J; Shi W; Wang L; Zheng Y; Sun Y
Theranostics; 2021; 11(7):3392-3416. PubMed ID: 33537094
[No Abstract] [Full Text] [Related]
15. Dual phosphoinositide 3-kinase/mammalian target of rapamycin blockade is an effective radiosensitizing strategy for the treatment of non-small cell lung cancer harboring K-RAS mutations.
Konstantinidou G; Bey EA; Rabellino A; Schuster K; Maira MS; Gazdar AF; Amici A; Boothman DA; Scaglioni PP
Cancer Res; 2009 Oct; 69(19):7644-52. PubMed ID: 19789349
[TBL] [Abstract][Full Text] [Related]
16. Kruppel-like factor 5 is not required for K-RasG12D lung tumorigenesis, but represses ABCG2 expression and is associated with better disease-specific survival.
Meyer SE; Hasenstein JR; Baktula A; Velu CS; Xu Y; Wan H; Whitsett JA; Gilks CB; Grimes HL
Am J Pathol; 2010 Sep; 177(3):1503-13. PubMed ID: 20639455
[TBL] [Abstract][Full Text] [Related]
17. KRAS-mutation status dependent effect of zoledronic acid in human non-small cell cancer preclinical models.
Kenessey I; Kói K; Horváth O; Cserepes M; Molnár D; Izsák V; Dobos J; Hegedűs B; Tóvári J; Tímár J
Oncotarget; 2016 Nov; 7(48):79503-79514. PubMed ID: 27780929
[TBL] [Abstract][Full Text] [Related]
18. Down-regulation of Sprouty2 in non-small cell lung cancer contributes to tumor malignancy via extracellular signal-regulated kinase pathway-dependent and -independent mechanisms.
Sutterlüty H; Mayer CE; Setinek U; Attems J; Ovtcharov S; Mikula M; Mikulits W; Micksche M; Berger W
Mol Cancer Res; 2007 May; 5(5):509-20. PubMed ID: 17510316
[TBL] [Abstract][Full Text] [Related]
19. Restoration of mutant K-Ras repressed miR-199b inhibits K-Ras mutant non-small cell lung cancer progression.
Jin H; Jang Y; Cheng N; Li Q; Cui PF; Zhou ZW; Jiang HL; Cho MH; Westover KD; Tan QY; Xu CX
J Exp Clin Cancer Res; 2019 Apr; 38(1):165. PubMed ID: 30987652
[TBL] [Abstract][Full Text] [Related]
20. Scrib heterozygosity predisposes to lung cancer and cooperates with KRas hyperactivation to accelerate lung cancer progression in vivo.
Elsum IA; Yates LL; Pearson HB; Phesse TJ; Long F; O'Donoghue R; Ernst M; Cullinane C; Humbert PO
Oncogene; 2014 Nov; 33(48):5523-33. PubMed ID: 24276238
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
